利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.023 秒)

    Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition
    1.
    发明申请
    Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition 审中-公开
    诊断与淀粉样蛋白沉积相关的疾病的原型形式的方法

    公开(公告)号：US20080286202A1

    公开(公告)日：2008-11-20

    申请号：US11666084

    申请日：2005-07-01

    申请人： William E. Klunk ,  Chester A. Mathis Jr.

    发明人： William E. Klunk ,  Chester A. Mathis Jr.

    IPC分类号： A61K51/04 ,  A61K49/00 ,  A61K49/04 ,  C07D277/66 ,  A61K49/10

    CPC分类号： A61K51/0478

    摘要： A method of identifying a patient as prodromal to a disease associated with amyloid deposition by imaging techniques is provided. In addition, a method of identifying amyloid deposition diseases in patients who present with a dementing disorder of questionable etiology by imaging techniques is provided. The methods discloses substances which are used for imaging and generating data which can be used to determine progress of an asymptomatic patient to a disease associated with amyloid deposition, or to identify amyloid deposition diseases in patients who present with a dementing disorder of questionable etiology.

    摘要翻译： 提供了通过成像技术将患者识别为与淀粉样蛋白沉积相关的疾病的前驱性的方法。 另外，提供了一种通过成像技术鉴定出具有可疑病因的痴呆病症的患者中淀粉样蛋白沉积疾病的方法。 该方法公开了用于成像和产生数据的物质，其可以用于确定无症状患者对与淀粉样蛋白沉积相关的疾病的进展，或鉴定存在具有可疑病因的痴呆病症的患者中的淀粉样蛋白沉积疾病。

    Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition
    6.
    发明授权
    Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition 有权
    硫磺衍生物用于阿尔茨海默病的止血诊断和淀粉样蛋白沉积的体内成像和预防

    公开(公告)号：US07351401B2

    公开(公告)日：2008-04-01

    申请号：US10859600

    申请日：2004-06-03

    申请人： William E. Klunk ,  Chester A. Mathis, Jr. ,  Yanming Wang

    发明人： William E. Klunk ,  Chester A. Mathis, Jr. ,  Yanming Wang

    IPC分类号： A61K51/00 ,  A61M36/14

    CPC分类号： A61K31/5415 ,  A61K31/428 ,  A61K51/0497 ,  C07B2200/05 ,  C07D277/64 ,  C07D277/66

    摘要： This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

    摘要翻译： 本发明涉及新型硫黄素衍生物，在例如具有神经炎斑块的患者的体内成像中使用衍生物的方法，包含硫代黄素衍生物的药物组合物和合成该化合物的方法。 该化合物特别用于诊断和治疗患有神经炎斑块积聚的疾病的患者。 疾病状态或疾病包括但不限于阿尔茨海默病，家族性阿尔茨海默氏病，唐氏综合征和载脂蛋白E4等位基因的纯合子。

    Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
    8.
    发明授权
    Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies 有权
    淀粉样蛋白成像作为抗淀粉样蛋白疗法功效的替代标记物

    公开(公告)号：US08343457B2

    公开(公告)日：2013-01-01

    申请号：US13412823

    申请日：2012-03-06

    申请人： William E. Klunk ,  Chester A. Mathis, Jr.

    发明人： William E. Klunk ,  Chester A. Mathis, Jr.

    IPC分类号： A61K49/00 ,  A61K51/00

    CPC分类号： A61K51/0453 ,  A61K49/0002 ,  A61K49/0438 ,  A61K49/10 ,  A61K51/0474

    摘要： The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.

    摘要翻译： 用于确定治疗淀粉样变性的疗效的本方法涉及向有需要的患者施用式（I）或式（II）化合物或结构1-45并使患者成像。 在所述成像之后，向所述患者施用至少一种抗淀粉样蛋白剂。 然后，向患者施用有效量的式（I）或式（II）或结构1-45的化合物，并再次对患者进行成像。 最后，将用抗淀粉样蛋白剂治疗之前患者淀粉样蛋白沉积的基线水平与用抗淀粉样蛋白剂治疗后患者淀粉样沉积的水平进行比较。

    Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
    10.
    发明授权
    Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies 有权
    淀粉样蛋白成像作为抗淀粉样蛋白疗法功效的替代标记物

    公开(公告)号：US08147798B2

    公开(公告)日：2012-04-03

    申请号：US11666083

    申请日：2005-07-01

    申请人： William E. Klunk ,  Chester A. Mathis, Jr.

    发明人： William E. Klunk ,  Chester A. Mathis, Jr.

    IPC分类号： A61K49/00 ,  A61K51/00

    CPC分类号： A61K51/0453 ,  A61K49/0002 ,  A61K49/0438 ,  A61K49/10 ,  A61K51/0474

    摘要： The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.

    摘要翻译： 用于确定治疗淀粉样变性的疗效的本方法涉及向有需要的患者施用式（I）或式（II）化合物或结构1-45并使患者成像。 在所述成像之后，向所述患者施用至少一种抗淀粉样蛋白剂。 然后，向患者施用有效量的式（I）或式（II）或结构1-45的化合物，并再次对患者进行成像。 最后，将用抗淀粉样蛋白剂治疗之前患者淀粉样蛋白沉积的基线水平与用抗淀粉样蛋白剂治疗后患者淀粉样沉积的水平进行比较。